Judith Hasko
WilmerHalePharmaceutical companies, academic institutions and investors come to WilmerHale for advice on critical transactions, including M&A, joint ventures and strategic alliances, in addition to being entrusted with complex patent disputes. Stuart Falber is sought after by a range of established players and new market entrants, including VC investors, for IPOs, spinoffs and licensing deals, leading the team alongside Lisa Pirozzolo, who represents clients in patent infringement and contractual litigation; both are based in Boston. In Washington DC, Amy Wigmore brings further litigious experience, handling a range of matters under the Hatch-Waxman Act and concerning biosimilars. Judith Hasko joined in Palo from Latham & Watkins LLP in June 2024, bringing significant experience.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'Our WilmerHale team is made up of top notch associates that provide spot on and good, practical advice and solutions. They are extremely hardworking and happy to stand shoulder to shoulder with us.'
- 'The partners I've worked with are more than up to the challenge and are adept at quickly working through complex contractual issues.'
Key clients
- Revvity
- Bristol Myers-Squibb Company
- PTC Therapeutics
- AVEO Oncology
- Exelixis, Inc.
- Cybrexa Therapeutics
- Quest Diagnostics
- Verve Therapeutics
- Becton, Dickinson and Company
- Akouos, Inc.
- Roche Diagnostics
- Apellis Pharmaceuticals
- Braintree Laboratories
- IVERIC Bio
- Nuvalent, Inc.
- Carisma Therapeutics
- Voyager Therapeutics
- Flare Therapeutics
- Astria Therapeutics
- Decibel Therapeutics
- Georgiamune, Inc.
Work highlights
- Represented Revvity in its agreement to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital for $2.45bn in cash.
- Represented Gilead Sciences when a federal jury sided with the pharmaceutical company against the US Government in a precedent-setting patent infringement trial centered on two HIV-prevention drugs that had been developed by Gilead: Truvada and Descovy.
- Represented PTC Therapeutics, Inc. in its agreement with Royalty Pharma plc. to monetize PTC’s remaining interests in its Evrysdi royalty stream for up to $1.5bn.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
The lawyer(s) leading their teams.
Stuart Falber, Lisa Pirozzolo